<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1084">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02249351</url>
  </required_header>
  <id_info>
    <org_study_id>506.209</org_study_id>
    <nct_id>NCT02249351</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Talsaclidine (Free Base) in Patients With Mild to Moderate Dementia of Alzheimer Type</brief_title>
  <official_title>Efficacy and Safety of 48 mg Talsaclidine (Free Base) Tid po (Panel 1) and 60 mg Talsaclidine (Free Base) Tid po (Panel 2) for 12 Weeks in a Double-blind, Randomised, Placebo-controlled Within Escalating Dose Panels in 150 Patients With Mild to Moderate Dementia of Alzheimer Type</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to assess symptomatic efficacy, safety and tolerability of talsaclidine in patients&#xD;
      with mild to moderate dementia of Alzheimer type&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>December 1999</start_date>
  <primary_completion_date type="Actual">May 2000</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Alzheimer's Disease Assessment Scale cognitive part (ADAScog)</measure>
    <time_frame>Baseline, week 4, 8, 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in ADAScog (extension)</measure>
    <time_frame>Baseline, week 4, 8, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ADAScog (Total)</measure>
    <time_frame>Baseline, week 4, 8, 12</time_frame>
    <description>Defined as ADAScog + ADAScog(extension)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mini mental state (MMS)</measure>
    <time_frame>Screening, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in neuropsychiatric inventory (NP)</measure>
    <time_frame>Baseline, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hamilton Depression Rating Scale (HAMD 17 item scale)</measure>
    <time_frame>Screening, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in instrumental activity of daily living (IADL)</measure>
    <time_frame>Baseline, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in living status rated on a 6-point scale</measure>
    <time_frame>Baseline, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinician's global impression rated with Alzheimer's Disease cooperative Study - Clinical Global Impression of Change (ADCS-CGIC)</measure>
    <time_frame>Baseline, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Talsaclidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talsaclidine</intervention_name>
    <arm_group_label>Talsaclidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patient, age: over 40 years (lower age if genetic Dementia of Alzheimer&#xD;
             Type (DAT) is documented). Patients over 85 years need to be in a clinically stable&#xD;
             state (investigator's judgement)&#xD;
&#xD;
          -  Patient's educational level is &gt; 4 years&#xD;
&#xD;
          -  Patient is able to understand the patient information and give informed consent&#xD;
&#xD;
          -  Patient has given written informed consent in accordance with Good Clinical Practice&#xD;
             and local legislation&#xD;
&#xD;
          -  Patient has a relative or caregiver who is willing and capable to support the clinical&#xD;
             trial; his/her written informed consent is optional&#xD;
&#xD;
          -  Body weight: ≥ 50 kg and within +/- 30% of normal weight (Broca index)&#xD;
&#xD;
          -  Diagnosis of DAT by the National Institute of Neurological and communicative&#xD;
             Disorders-Alzheimer's Disease and Related Disorder Association (NINCDS-ADRDA) criteria&#xD;
&#xD;
          -  MMS-score 10 - 24 inclusive&#xD;
&#xD;
          -  Rosen ischemia score is lower or equal to two&#xD;
&#xD;
          -  Patient is able to complete the trial examinations, to hear, speak, read and write in&#xD;
             a basic way and primary sensorial functions are intact&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any dementia of vascular genesis (Rosen ischemia score &gt; 2)&#xD;
&#xD;
          -  Magnetic Resonance Imaging (MRI) or Computer Tomogram (CT) findings make the diagnosis&#xD;
             of DAT unlikely (with a scan performed within 12 months of study entry)&#xD;
&#xD;
          -  Any stroke history&#xD;
&#xD;
          -  All secondary dementia (exclusion diagnosis defined by the NINCDS-ADRDA criteria) as a&#xD;
             late complication of:&#xD;
&#xD;
               -  Cranio-cerebral trauma&#xD;
&#xD;
               -  Intoxication (incl. history of alcohol and drug abuse)&#xD;
&#xD;
               -  Cerebral infections (e.g. neurosyphilis)&#xD;
&#xD;
               -  Thyroid dysfunction&#xD;
&#xD;
          -  Cerebral dysfunction due to metabolic disorders&#xD;
&#xD;
          -  Possible reversible dementias secondary to a deficiency of vitamin B12, folic acid or&#xD;
             thyroid hormone. Replacement therapy must be started three months before visit 1 in&#xD;
             order to exclude dementia due to these deficiencies.&#xD;
&#xD;
          -  Brain tumour (benign tumours found on CT not felt to be clinically relevant may be&#xD;
             included, i.e.: meningioma)&#xD;
&#xD;
          -  Down's syndrome, Parkinson's disease, Huntington's chorea, Diffuse Lewy Body Disease&#xD;
             (as measured by the McKeith Criteria and specified in CTM)&#xD;
&#xD;
          -  Multiple sclerosis&#xD;
&#xD;
          -  Major depression with a score of &lt;=16 on the Hamilton Depression Rating Scale (HAMD)&#xD;
             17 item scale&#xD;
&#xD;
          -  Depressive pseudodementia&#xD;
&#xD;
          -  Mental retardation&#xD;
&#xD;
          -  Hydrocephalus&#xD;
&#xD;
          -  Epilepsy&#xD;
&#xD;
          -  Endogenous psychoses (schizophrenia)&#xD;
&#xD;
          -  Untreated or poorly compensated hypertension (Blood Pressure systolic &gt; 180 and/or&#xD;
             diastolic &gt; 110 mmHg)&#xD;
&#xD;
          -  Hypertension being treated with reserpine, clonidine or β-blockers&#xD;
&#xD;
          -  Severe heart disease (NYHA: III and IV)&#xD;
&#xD;
          -  Any cardiac arrhythmias (atrial or ventricular) including bradycardia with a rate of &lt;&#xD;
             50 bpm, arrhythmias due to second or third degree blocks and Lown: II-IV,&#xD;
             Electrocardiogram &gt; 30 ventricular extrasystoles/hour, multifocal or multiform and&#xD;
             repetitive forms of ventricular extrasystoles, pacemakers are allowed&#xD;
&#xD;
          -  Bronchial asthma with phases of exacerbation, or inducible by aspirin or other&#xD;
             Nonsteroidal anti-inflammatory drugs, requiring acute pharmacologic intervention&#xD;
             during the previous year&#xD;
&#xD;
          -  Diabetes, type I or II, under active treatment with either insulin or an oral agent,&#xD;
             diabetes controlled by diet and exercise alone is not excluded&#xD;
&#xD;
          -  Renal insufficiency with a calculated creatinine clearance of less than 50 ml/min&#xD;
&#xD;
          -  Abnormal urinalysis results as defined by:&#xD;
&#xD;
               -  a bacterial colony count of greater than 100,000/ml or&#xD;
&#xD;
               -  more than 10 leukocytes per high power field with more than 2 granular casts per&#xD;
                  low power field or&#xD;
&#xD;
               -  more than 10 red blood cells per high power field or&#xD;
&#xD;
               -  proteinuria &gt;+ 1 (equivalent to &gt; 30 mg/dl) and with a ratio of urine&#xD;
                  protein/urine creatinine &gt; 0.3&#xD;
&#xD;
          -  History of chronic urinary tract infection or recent urinary tract infection over the&#xD;
             past six months&#xD;
&#xD;
          -  History of renal stones within the past six months&#xD;
&#xD;
          -  Acute hepatic disorder (liver enzymes above 50 % upper normal limit)&#xD;
&#xD;
          -  Chronic hepatitis within the last two years (positive hepatitis titer, Hepatitis A&#xD;
             Virus, Hepatitis B Virus, Hepatitis C Virus, cytomegalovirus, Epstein-Barr virus or&#xD;
             abnormal immunological values (positive immunoglobulin M(IgM)/IgG) are allowed if all&#xD;
             liver enzymes are within the normal range)&#xD;
&#xD;
          -  History of liver disease within 2 years secondary to drug intoxication of any cause&#xD;
             including drug intoxication (e.g. narcotics, cytostatics etc.)&#xD;
&#xD;
          -  Patients with obvious symptoms of dehydration&#xD;
&#xD;
          -  Abuse or dependence on drugs or other hepatotoxic agents by history or drug screen. A&#xD;
             history of alcohol abuse within the last 10 years will also exclude the patient&#xD;
&#xD;
          -  Neoplasm currently active or likely to recur, or in need of treatment (except basal&#xD;
             cell carcinoma)&#xD;
&#xD;
          -  Participation in another clinical trial within the last four weeks, or previous&#xD;
             participation in a talsaclidine trial; patients who have been entered into panel 1 are&#xD;
             not eligible for inclusion in panel 2&#xD;
&#xD;
          -  Pregnant and lactating woman, woman with childbearing potential not using an approved&#xD;
             method of contraception&#xD;
&#xD;
          -  Poor ability of the patient or caregiver/family to comply with protocol requirements&#xD;
             as assessed by the investigator&#xD;
&#xD;
          -  A list of excluded medications is attached to the protocol. These medications have to&#xD;
             be replaced at least four weeks before the trial medication is started. If replacement&#xD;
             in not clinically advisable, then the patient has to be excluded from the trial&#xD;
&#xD;
          -  In Germany, patients with the following additional diagnosis are excluded&#xD;
&#xD;
               -  manifest angina pectoris as well as&#xD;
&#xD;
               -  peripheral arterial circulatory disturbances&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>September 23, 2014</study_first_submitted>
  <study_first_submitted_qc>September 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2014</study_first_posted>
  <last_update_submitted>September 25, 2014</last_update_submitted>
  <last_update_submitted_qc>September 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

